By Michele Maatouk
Date: Wednesday 01 Oct 2025
(Sharecast News) - US President Donald Trump's 'Most Favoured Nation' deal with Pfizer could be a bellwether for the pharmaceutical sector and reassure investors over a broadly manageable impact, JPMorgan said in a research note
Patent Woes Threaten Drug Firms | 07-Mar-2011 | New York Times |
Stocks push higher on deals and strong earnings | 09-Feb-2011 | USA Today |
Dow soars to close above 12,000 | 02-Feb-2011 | Wall Street Journal |
Pfizer To Close UK Plant And Axe 2,400 Jobs | 01-Feb-2011 | Sky News |
Despite good earnings reports, stocks tumble | 21-Oct-2009 | Wall Street Journal |
Currency | US Dollars |
Share Price | $ 25.24 |
Change Today | $ -0.44 |
% Change | -1.71 % |
52 Week High | $30.19 |
52 Week Low | $21.59 |
Volume | 47,084,374 |
Shares Issued | 5,667m |
Market Cap | $143,035m |
Beta | 0.46 |
RiskGrade | 102 |
Time | Volume / Share Price |
16:00 | 5,162,381 @ $25.24 |
15:59 | 100 @ $25.23 |
15:59 | 100 @ $25.22 |
15:59 | 238 @ $25.23 |
15:59 | 100 @ $25.23 |
You are here: research